Author(s):
Prakash Nathaniel Kumar Sarella, Veera Kumari Vendi, Anil Kumar Vipparthi, Surekha Valluri, Srujala Vegi
Email(s):
sarellaprakash@acop.edu.in
DOI:
10.52711/2231-5659.2024.00046 
Address:
Prakash Nathaniel Kumar Sarella*, Veera Kumari Vendi, Anil Kumar Vipparthi, Surekha Valluri, Srujala Vegi
Department of Pharmaceutics, Aditya College of Pharmacy, ADB Road, Surampalem, Kakinada 533437, Andhra Pradesh, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 3,
Year - 2024
ABSTRACT:
In recent years, the field of drug delivery has experienced remarkable progress as researchers strive to enhance the efficacy and safety of pharmaceutical treatments while ensuring patient convenience and compliance. One notable innovation that has garnered significant attention is the development of proniosomes. Proniosomes represent a novel drug delivery platform that merges the advantageous features of niosomes and liposomes while effectively addressing their inherent limitations. Unlike traditional liquid-based liposomes and niosomes, proniosomes are formulated as dry, free-flowing powders or granules. This dry presentation offers several key benefits, including improved stability during storage and transportation, reducing the risk of drug degradation and extending shelf life. Upon contact with an appropriate medium, such as body fluids or a dispersion medium, these proniosomes readily transform into niosomal structures. This characteristic transformation ensures the controlled release of the encapsulated drug, leading to prolonged drug action and potentially reduced dosing frequency, enhancing patient adherence to therapy. Central to the success of proniosomes is the application of nanotechnology, a discipline focused on manipulating materials at the nanoscale. By leveraging nanotechnology, researchers have achieved significant improvements in the physicochemical properties and drug-loading capabilities of proniosomes. Nanoscale drug carriers can traverse biological barriers more effectively, leading to improved bioavailability and targeted delivery to specific tissues or cells. The purpose of this review article is to provide a comprehensive overview of the recent advances in proniosomes and their application in harnessing nanotechnology for enhanced drug delivery.
Cite this article:
Prakash Nathaniel Kumar Sarella, Veera Kumari Vendi, Anil Kumar Vipparthi, Surekha Valluri, Srujala Vegi. Advances in Proniosomes: Harnessing Nanotechnology for Enhanced Drug Delivery. Asian Journal of Research in Pharmaceutical Sciences. 2024; 14(3):279-6. doi: 10.52711/2231-5659.2024.00046
Cite(Electronic):
Prakash Nathaniel Kumar Sarella, Veera Kumari Vendi, Anil Kumar Vipparthi, Surekha Valluri, Srujala Vegi. Advances in Proniosomes: Harnessing Nanotechnology for Enhanced Drug Delivery. Asian Journal of Research in Pharmaceutical Sciences. 2024; 14(3):279-6. doi: 10.52711/2231-5659.2024.00046 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2024-14-3-15
REFERENCES:
1. Jangam RP, Thombre AN, Gaikwad NP. A Review: Proniosomes as a Novel Drug Delivery System. Asian Jour Pharm and Technol. 2017; 7(3): 166. doi: 10.5958/2231-5713.2017.00027.7
2. Srikanth, Kumar YA, Setty CM. Formulation and Evaluation of Maltodextrin Based Doxorubicin HCl Proniosomes. Rese Jour of Pharm and Technol. 2019; 12(6): 2776. doi: 10.5958/0974-360X.2019.00466.9
3. Arvapalli S, Anka Rao A. Preparation, Characterization and Optimization of Maltodextrin based Efavirenz loaded Proniosomes using Box Behnken Design: In vitro and ex-vivo permeation study. Research Journal of Pharmacy and Technology. 2023: 669-75. doi: 10.52711/0974-360X.2023.00114
4. Srikanth K, Nappinnai M, Gupta VRM. Proniosomes: A novel drug carrier system. Research Journal of Pharmacy and Technology. 2010; 3(3): 709-11.
5. Ahmad W, Khan T, Basit I, Imran J. A Comprehensive Review on Targeted Drug Delivery System. AJPR. 2022:335-40. doi: 10.52711/2231-5691.2022.00053
6. Devi GC, Kumar AE. Microbubbles-A Potential Novel Targeted Drug Delivery. Research Journal of Pharmacy and Technology. 2019; 12(5): 2511-6. doi: 10.5958/0974-360X.2019.00423.2
7. Ajrin M, Anjum F. Proniosome: A Promising Approach for Vesicular Drug Delivery. Turk J Pharm Sci. 2022; 19(4): 462-75. doi: 10.4274/tjps.galenos.2021.53533
8. Pagar KR, Khandbahale SV. A Review on Novel Drug Delivery System: A Recent Trend. Asian Jour Pharm and Technol. 2019; 9(2): 135. doi: 10.5958/2231-5713.2019.00023.0
9. Praveen K, Balamurugan K. Targeted Drug Delivery through Nanosponges and its Approach. Rese Jour of Pharm and Technol. 2020; 13(7): 3524. doi: 10.5958/0974-360X.2020.00624.1
10. Blazek-Welsh AI, Rhodes DG. Maltodextrin-based proniosomes. AAPS Pharm Sci. 2001;3(1):1-8. doi: 10.1208/ps030101
11. El Maghraby GM, Ahmed AA, Osman MA. Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery. Saudi Pharm J. 2015; 23(1): 67-74. doi: 10.1016/j.jsps.2014.05.001
12. Ibrahim MMA, Sammour OA, Hammad MA, Megrab NA. In Vitro Evaluation of Proniosomes as a Drug Carrier for Flurbiprofen. AAPS Pharm Sci Tech. 2008;9(3):782-90. doi: 10.1208/s12249-008-9114-0
13. Nasr M. In Vitro and In Vivo Evaluation of Proniosomes Containing Celecoxib for Oral Administration. AAPS PharmSciTech 2010;11(1):85-9. doi: 10.1208/s12249-009-9364-5
14. Khatoon M, Shah KU, Din FU, Shah SU, Rehman AU, Dilawar N, et al. Proniosomes derived niosomes: recent advancements in drug delivery and targeting. Drug Deliv. 24(2):56-69. doi: 10.1080/10717544.2017.1384520
15. Radha GV, Rani TS, Sarvani B. A review on proniosomal drug delivery system for targeted drug action. J Basic Clin Pharm. 2013; 4(2): 42-8. doi: 10.4103/0976-0105.113609
16. Shah H, Nair AB, Shah J, Bharadia P, Al-Dhubiab BE. Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats. DARU Journal of Pharmaceutical Sciences. 2019; 27(1): 59-70. doi: 10.1007/s40199-019-00242-x
17. Shehata TM, Ibrahim MM, Elsewedy HS. Curcumin Niosomes Prepared from Proniosomal Gels: In Vitro Skin Permeability, Kinetic and In Vivo Studies. Polymers (Basel). 2021; 13(5): 791. doi: 10.3390/polym13050791
18. Shehata TM, Abdallah MH, Ibrahim MM. Proniosomal Oral Tablets for Controlled Delivery and Enhanced Pharmacokinetic Properties of Acemetacin. AAPS Pharm Sci Tech. 2014; 16(2): 375-83. doi: 10.1208/s12249-014-0233-5
19. Sahu K, Pathak R, Agrawal N, Banjare P, Sharma H, Sahu G. A Review of the Novel Drug Delivery System used in the Treatment of Cancer. Rese Jour Pharmaceut Dosag Form and Technol. 2019; 11(3): 199. doi: 10.5958/0975-4377.2019.00035.1
20. Emad Eldeeb A, Salah S, Ghorab M. Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study. Drug Deliv. 2019; 26(1): 509-21. doi: 10.1080/10717544.2019.1609622
21. Abu El-Enin ASM, Khalifa MKA, Dawaba AM, Dawaba HM. Proniosomal gel-mediated topical delivery of fluconazole: Development, in vitro characterization, and microbiological evaluation. J Adv Pharm Technol Res. 2019; 10(1): 20-6. doi: 10.4103/japtr.JAPTR_332_18
22. Solanki N, Prajapati S. Self emulsifying drug delivery system (SEDDS): a review. International Journal of Pharmaceutical Research and Bio-science. 2012; 1.
23. Solanki AB, Parikh JR, Parikh RH. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level box-behnken design. AAPS Pharm Sci Tech. 2007; 8(4): 43. doi: 10.1208/pt0804086
24. Teaima MH, Yasser M, El-Nabarawi MA, Helal DA. Proniosomal Telmisartan Tablets: Formulation, in vitro Evaluation and in vivo Comparative Pharmacokinetic Study in Rabbits. Drug Des Devel Ther. 2020; 14: 1319-31. doi: 10.2147/DDDT.S245013
25. Rajabalaya R, Leen G, Chellian J, Chakravarthi S, David SR. Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder. Pharmaceutics. 2016; 8(3): 27. doi: 10.3390/pharmaceutics8030027
26. Pinzaru I, Tanase A, Enatescu V, Coricovac D, Bociort F, Marcovici I, et al. Proniosomal Gel for Topical Delivery of Rutin: Preparation, Physicochemical Characterization and In Vitro Toxicological Profile Using 3D Reconstructed Human Epidermis Tissue and 2D Cells. Antioxidants (Basel). 2021; 10(1): 85. doi: 10.3390/antiox10010085
27. Gharbavi M, Amani J, Kheiri-Manjili H, Danafar H, Sharafi A. Niosome: A Promising Nanocarrier for Natural Drug Delivery through Blood-Brain Barrier. Adv Pharmacol Sci. 2018; 2018: 6847971. doi: 10.1155/2018/6847971
28. Ge X, Wei M, He S, Yuan WE. Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery. Pharmaceutics. 2019; 11(2): 55. doi: 10.3390/pharmaceutics11020055
29. Fathi-Azarbayjani A, Ng KX, Chan YW, Chan SY. Lipid Vesicles for the Skin Delivery of Diclofenac: Cerosomes vs. Other Lipid Suspensions. Adv Pharm Bull. 2015; 5(1): 25-33. doi: 10.5681/apb.2015.004